Vitamin A Derivative
ALK-001 for Stargardt Disease
This trial tests a special type of vitamin A called ALK-001 to see if it can safely slow down vision loss in people with Stargardt disease by reducing harmful substances in the eye. ALK-001 is designed to reduce the accumulation of toxic substances in the retina, which are associated with vision loss in Stargardt disease.
Popular Filters
Trials for STGD Patients
Complement Factor C5 Inhibitor
Zimura for Stargardt Disease
This trial is testing an eye injection medication to help people with Stargardt disease, a genetic condition that leads to vision loss. The medication aims to block harmful processes in the eye to prevent further vision loss.
Stem Cell Therapy
Stem Cell Therapy for Retinal and Optic Nerve Disorders
This trial will use stem cells from patients' own bone marrow to treat severe vision loss caused by retinal or optic nerve damage. The stem cells will be injected into the eye to help repair the damaged tissues. SCOTS is the largest ophthalmology stem cell study registered at the National Institutes of Health, using autologous bone marrow-derived stem cells for retinal and optic nerve diseases.
Trials for Age-Related Macular Degeneration Patients
Behavioural Intervention
Scotoma Awareness Training for Low Vision
This trial tests a new training method for older adults with Macular Degeneration, a condition causing central vision loss. The training uses a simulated blind spot to help patients become aware of their vision loss and develop new ways to see better. By making patients aware of their blind spot, the training aims to improve their vision and daily functioning. Eccentric viewing training has been shown to improve near visual acuity, reading speed, and daily functioning in people with central vision loss.
Anti-VEGF Monoclonal Antibody
Zifibancimig for Age-Related Macular Degeneration
This trial is testing a new treatment called zifibancimig for people with a serious eye condition known as neovascular age-related macular degeneration (nAMD). The treatment is given either as an injection into the eye or through a small implant. It works by stopping harmful blood vessels from growing in the eye, which can help protect or improve vision.
Trials for ABCA4 Positive Patients
Complement Factor C5 Inhibitor
Zimura for Stargardt Disease
This trial is testing an eye injection medication to help people with Stargardt disease, a genetic condition that leads to vision loss. The medication aims to block harmful processes in the eye to prevent further vision loss.
Gene Therapy
OCU410ST for Stargardt Disease
This trial tests OCU410ST, a treatment using a harmless virus to deliver a helpful gene into the eye, for children and young adults with Stargardt disease. The gene helps manage fat buildup, stress, and inflammation in the eye.
Tinlarebant for Stargardt Disease
This trial is testing a medication called tinlarebant to see if it can slow down eye damage in teenagers with a condition called STGD1. About 90 participants will take tinlarebant for an extended period. The goal is to see if tinlarebant can help prevent their vision from getting worse.
Trials With No Placebo
Behavioural Intervention
Scotoma Awareness Training for Low Vision
This trial tests a new training method for older adults with Macular Degeneration, a condition causing central vision loss. The training uses a simulated blind spot to help patients become aware of their vision loss and develop new ways to see better. By making patients aware of their blind spot, the training aims to improve their vision and daily functioning. Eccentric viewing training has been shown to improve near visual acuity, reading speed, and daily functioning in people with central vision loss.
Anti-VEGF Monoclonal Antibody
Zifibancimig for Age-Related Macular Degeneration
This trial is testing a new treatment called zifibancimig for people with a serious eye condition known as neovascular age-related macular degeneration (nAMD). The treatment is given either as an injection into the eye or through a small implant. It works by stopping harmful blood vessels from growing in the eye, which can help protect or improve vision.
Frequently Asked Questions
Introduction to stargardt disease
What are the top hospitals conducting stargardt disease research?
When it comes to advancing research and treatment options for Stargardt disease, several hospitals are leading the way. In Hagerstown, Cumberland Valley Retina Consultants has made significant strides with four active trials dedicated to this rare condition. Over the years, they have conducted a total of 16 trials since their first recorded investigation in 2012. Similarly, in Dallas, the Retina Foundation of the Southwest is actively engaged in four ongoing stargardt disease trials. With a history that dates back to their initial trial in 2012, they have completed an impressive tally of 20 studies related to this degenerative eye disorder.
Meanwhile, at Retina Consultants of Texas located in Bellaire and Retina Research Institute of Texas situated in Abilene—both renowned institutions—are also contributing significantly to the field of stargardt disease research. Each hospital currently conducts four active clinical trials focused on understanding and combating this genetic condition. Having embarked on their first stargardt disease trial more recently (in Bellaire's case dating back only to 2015), these hospitals have already achieved remarkable milestones by conducting a combined total of 24 and 34 trials respectively.
Notably last but certainly not least,making valuable contributions from East Florida Eye Institute based out Stuart,the establishment carrying three concurrent clinical tests intended towards fighting against Stargart diseases.It interestingly stood as one among those few pioneers who accomplished eleven previous investigations into such cases;dating its roots all way long ago till2005.
These leading hospitals across different locations showcase their commitment and dedication towards tackling Stargardt disease—a condition that affects individuals' central vision as a result of genetic mutations.With each new trial initiated,and with every advancement made,the hope for improved treatments grows brighter.The collective efforts being undertaken by these medical centers pave the path toward potential breakthroughs,serving as beacons for patients worldwide affected by this challenging disease
Which are the best cities for stargardt disease clinical trials?
When it comes to stargardt disease clinical trials, several cities have emerged as key hubs for research and innovation. Phoenix, Arizona, Dallas, Texas, Salt Lake City, Utah, Portland Oregon, and Gainesville Florida are among the top locations offering active trials in this field. These cities are conducting studies on various potential treatments such as IONIS-FB-LRx, Zimura, Avacincaptad pegol 2 mg intravitreal injection and Tinlarebant among others. With their commitment to advancing knowledge and finding effective therapies for stargardt disease sufferers, these cities provide invaluable opportunities for participation in groundbreaking clinical trials.
Which are the top treatments for stargardt disease being explored in clinical trials?
The search for effective treatments for Stargardt disease is ongoing, with several potential options being explored in clinical trials. Leading the pack is ALK-001, currently involved in two active trials specifically targeting Stargardt disease. This innovative treatment made its first appearance on the medical landscape in 2015 and has since garnered a total of two dedicated trials. Additionally, there are promising developments involving avacincaptad pegol 2 mg intravitreal injection and 'Scotoma awareness' training, both new entries to the field with one active trial each. These cutting-edge approaches offer hope for individuals living with Stargardt disease as researchers continue their quest for effective interventions.
What are the most recent clinical trials for stargardt disease?
Promising developments are arising in the field of Stargardt disease, with recent clinical trials offering hope for patients. One such trial involves an experimental treatment utilizing low doses, aiming to assess its effectiveness and safety in treating this condition. Another study focuses on Part 1 of a larger trial targeting Stargardt disease specifically. Additionally, researchers are investigating the potential benefits of JNJ-81201887 at higher doses as a therapeutic option for this debilitating disease. A Phase 3 trial is also underway, evaluating the efficacy and safety of Avacincaptad pegol through intravitreal injection. Lastly, gene therapy using vMCO-010 exhibits promise as it progresses through Phase 2 trials. These innovative approaches hold significant potential for improving outcomes and quality of life for individuals affected by Stargardt disease.
What stargardt disease clinical trials were recently completed?
Several clinical trials for Stargardt disease, a debilitating inherited eye disorder, have recently concluded. In May 2022, Sandoz completed a trial investigating the potential of SOK583A1 to address this condition. Similarly, Kodiak Sciences Inc wrapped up their KSI-301 study in June 2021. Additionally, Maturi Raj K., M.D., P.C., finished their RBM-007 Injectable Solution trial in the same month. These milestones highlight the ongoing efforts to find effective treatments for Stargardt disease and bring hope to those impacted by this progressive visual impairment.